Results 11 to 20 of about 11,332,305 (264)

Monitoring of Amyloid Related Imaging Abnormalities: SWI vs T2*-GRE [PDF]

journal of prevention of Alzheimer's disease, The
Amyloid-β-directed monoclonal antibody therapies may lead to amyloid-related imaging abnormalities (ARIA). Clinical trials that formed the basis for the ARIA radiographic severity grading scale adopted by the approved drugs' labels utilized T2* gradient ...
Jeffrey L. Cummings, Diana M Sima, Philip Scheltens   +2 more
exaly   +7 more sources

Risk factors in developing amyloid related imaging abnormalities (ARIA) and clinical implications [PDF]

Frontiers in Neuroscience
Alzheimer’s disease (AD) affects over 6 million people over the age of 65. The advent of new anti-amyloid monoclonal antibodies as treatment for early Alzheimer’s disease these immunotherapeutics may slow disease progression but also pose significant ...
Sarah J. Doran, Russell P. Sawyer
doaj   +4 more sources

Amyloid-related imaging abnormalities (ARIA): radiological, biological and clinical characteristics [PDF]

Brain, 2023
Excess accumulation and aggregation of toxic soluble and insoluble amyloid-β species in the brain are a major hallmark of Alzheimer's disease. Randomized clinical trials show reduced brain amyloid-β deposits using monoclonal antibodies that target ...
Elhage, Aya, Hampel, Harald, Cho, Min, Aya Elhage, Liana G Apostolova, James A R Nicoll, Apostolova, Liana G., Harald Hampel, Alireza Atri, Min Cho, Atri, Alireza, Nicoll, James A. R., Nicoll, James A.R.   +12 more
core   +5 more sources

Amyloid-Related Imaging Abnormalities with Emerging Alzheimer Disease Therapeutics: Detection and Reporting Recommendations for Clinical Practice [PDF]

American Journal of Neuroradiology, 2022
Monoclonal antibodies are emerging disease-modifying therapies for Alzheimer disease that require brain MR imaging for eligibility assessment as well as for monitoring for amyloid-related imaging abnormalities.
Ramanan, VK, Cogswell, PM, Benzinger, TS, Jack, CR, Whitlow, CT, Barkhof, F, Raji, CA, Poussaint, TY, Barakos, JA   +8 more
core   +6 more sources

Evaluating Clinical Meaningfulness of Anti-β-Amyloid Therapies Amidst Amyloid-Related Imaging Abnormalities Concern in Alzheimer’s Disease [PDF]

Brain Communications
Alzheimer’s disease is the most prevalent form of dementia in the elderly, which is clinically characterized by a gradual and progressive deterioration of cognitive functions.
Paul Edison
exaly   +4 more sources

Imaging spectrum of amyloid-related imaging abnormalities associated with aducanumab immunotherapy

Frontiers in Radiology
Alzheimer's Disease (AD) is a leading cause of morbidity. Management of AD has traditionally been aimed at symptom relief rather than disease modification.
Houman Sotoudeh, Mohammadreza Alizadeh, Ramin Shahidi, Parnian Shobeiri, Zahra Saadatpour, C. Austin Wheeler, Marissa Natelson Love, Manoj Tanwar   +7 more
doaj   +3 more sources

Amyloid-beta antibody binding to cerebral amyloid angiopathy fibrils and risk for amyloid-related imaging abnormalities

Scientific Reports
Therapeutic antibodies have been developed to target amyloid-beta (Aβ), and some of these slow the progression of Alzheimer’s disease (AD). However, they can also cause adverse events known as amyloid-related imaging abnormalities with edema (ARIA-E). We
Linda Söderberg, Malin Johannesson, Eleni Gkanatsiou, Patrik Nygren, Nicolas Fritz, Olof Zachrisson, Adeline Rachalski, Anne-Sophie Svensson, Emily Button, Giacomo Dentoni, Gunilla Osswald, Lars Lannfelt, Christer Möller   +12 more
doaj   +2 more sources

Amyloid-related imaging abnormalities: manifestations, metrics and mechanisms

Nature Reviews Neurology
Three monoclonal antibodies directed against specific forms of the amyloid-β (Aβ) peptide have been granted accelerated or traditional approval by the FDA as treatments for Alzheimer disease, representing the first step towards bringing disease-modifying
Greenberg S. M., van Veluw S. J., Bax F., Bax, F.   +3 more
core   +3 more sources

FDG-PET versus Amyloid-PET Imaging for Diagnosis and Response Evaluation in Alzheimer’s Disease: Benefits and Pitfalls [PDF]

Diagnostics, 2023
In June 2021, the US Federal Drug and Food Administration (FDA) granted accelerated approval for the antibody aducanumab and, in January 2023, also for the antibody lecanemab, based on a perceived drug-induced removal of cerebral amyloid-beta as assessed
Poul F. Høilund-Carlsen, Mona-Elisabeth Revheim, Tommaso Costa, Kasper P. Kepp, Rudolph J. Castellani, George Perry, Abass Alavi, Jorge R. Barrio   +7 more
doaj   +2 more sources

Amyloid‐Related Imaging Abnormality (ARIA) Beyond the APOE‐ε4 Allele

Chronic Diseases and Translational Medicine
Monoclonal antibodies (mAbs) have made significant progress in the treatment of Alzheimer's disease (AD). However, mAbs are associated with adverse effects, including Amyloid‐Related Imaging Abnormality (ARIA), which manifests as edema or effusion (ARIA ...
Valentinus Besin, Farizky Martriano Humardani, Fenny Lanawati Yudiarto, Paulus Anam Ong, Sulistyo Emantoko Dwi Putra, Ratih Asmana Ningrum   +5 more
doaj   +4 more sources